Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis - caffeine, ergotamine tartrate - tablet - 1 , 100 mg

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amdipharma, ireland - caffeine,ergotamine tartrate,hydrochlorothiazide,eprosartan mesilate - tablet - 100,1,12.5,600 mg,

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

sandoz inc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 1 mg - cafergot (ergotamine tartrate and caffeine tablets, usp) is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so-called “histaminic cephalalgia”. coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ) , with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when cafergot (ergotamine tartrate and caffeine tablets, usp) was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ) . cafergot (ergotamine tart

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway d

Singapur - engleski - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - tablet, film coated - 100mg - lopinavir 100mg; ritonavir 25mg

Singapur - engleski - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - tablet, film coated - 200.0mg - lopinavir 200.0mg; ritonavir 50.0mg

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg (as a blend with silicon dioxide);  ;  ;  ; elvitegravir 150mg;  ;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg);   - tablet - active: cobicistat 150mg (as a blend with silicon dioxide)       elvitegravir 150mg     emtricitabine 200mg         tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg)   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f110095 sodium laurilsulfate - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment-na?ve; or virologically suppressed (hiv-1 rna genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; hypromellose; titanium dioxide; magnesium stearate; povidone; hyprolose; glucose; maize starch; propylene glycol; poloxamer - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in; acute pharyngitis, tonsillitis, and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis

Kanada - engleski - Health Canada

apotex inc - eletriptan (eletriptan hydrobromide) - tablet - 20mg - eletriptan (eletriptan hydrobromide) 20mg - selective serotonin agonists

Kanada - engleski - Health Canada

apotex inc - eletriptan (eletriptan hydrobromide) - tablet - 40mg - eletriptan (eletriptan hydrobromide) 40mg - selective serotonin agonists